Literature DB >> 9204910

Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes.

J M Kulak1, T A Nguyen, B M Olivera, J M McIntosh.   

Abstract

Activation of presynaptic nicotinic acetylcholine receptors (nAChRs) can induce the release of neurotransmitters such as dopamine and norepinephrine in the CNS. Accumulating evidence suggests that distinct nAChR subtypes are involved; however, it has been difficult to determine the subunit composition of these receptors, in part because of the lack of a sufficient variety of selective nAChR ligands. We present experimental data that at least two different nAChR complexes are involved in dopamine release, one of which has an alpha3/beta2 subunit interface. The recently discovered peptide alpha-conotoxin MII is a potent and selective inhibitor of rat nAChRs containing an interface formed by alpha3 and beta2 subunits. We used this peptide to examine nicotine-stimulated release of dopamine from rat striatal synaptosomes and of norepinephrine from hippocampal synaptosomes. MII (100 nM) blocks 34-49% of the nicotine-stimulated dopamine release, but not dopamine release evoked by elevated [K+]. Furthermore, two peptides structurally related to alpha-conotoxin MII, namely alpha-conotoxin MI (selective for alpha1beta1gammadelta nAChRs) and alpha-conotoxin ImI (selective for alpha7-containing nAChRs), have no effect on nicotine-stimulated dopamine release. The results indicate that one third to half of the dopamine release in the striatal preparation is mediated by nAChRs with an alpha3/beta2 subunit interface. In contrast, </=10% of nicotine-stimulated release of norepinephrine from hippocampal synaptosomes is modulated by nAChRs with alpha3/beta2 subunit interfaces.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9204910      PMCID: PMC6793802     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  39 in total

1.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.

Authors:  R Freedman; H Coon; M Myles-Worsley; A Orr-Urtreger; A Olincy; A Davis; M Polymeropoulos; J Holik; J Hopkins; M Hoff; J Rosenthal; M C Waldo; F Reimherr; P Wender; J Yaw; D A Young; C R Breese; C Adams; D Patterson; L E Adler; L Kruglyak; S Leonard; W Byerley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Effect of chronic nicotine treatment on nicotinic autoreceptor function and N-[3H]methylcarbamylcholine binding sites in the rat brain.

Authors:  P A Lapchak; D M Araujo; R Quirion; B Collier
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

3.  Hippocampal synaptic transmission enhanced by low concentrations of nicotine.

Authors:  R Gray; A S Rajan; K A Radcliffe; M Yakehiro; J A Dani
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse.

Authors:  A M Janson; K Fuxe; E Sundström; L F Agnati; M Goldstein
Journal:  Acta Physiol Scand       Date:  1988-04

Review 5.  Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons.

Authors:  D S McGehee; L W Role
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

6.  The amino terminal half of the nicotinic beta-subunit extracellular domain regulates the kinetics of inhibition by neuronal bungarotoxin.

Authors:  R L Papke; R M Duvoisin; S F Heinemann
Journal:  Proc Biol Sci       Date:  1993-05-22       Impact factor: 5.349

7.  Hippocampal nicotinic autoreceptors modulate acetylcholine release.

Authors:  G I Wilkie; P H Hutson; M W Stephens; P Whiting; S Wonnacott
Journal:  Biochem Soc Trans       Date:  1993-05       Impact factor: 5.407

8.  Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography.

Authors:  A Nordberg; P Hartvig; A Lilja; M Viitanen; K Amberla; H Lundqvist; Y Andersson; J Ulin; B Winblad; B Långström
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1990

9.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

Review 10.  The role of dopamine in drug abuse viewed from the perspective of its role in motivation.

Authors:  G Di Chiara
Journal:  Drug Alcohol Depend       Date:  1995-05       Impact factor: 4.492

View more
  56 in total

1.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Identification of N-terminal extracellular domain determinants in nicotinic acetylcholine receptor (nAChR) α6 subunits that influence effects of wild-type or mutant β3 subunits on function of α6β2*- or α6β4*-nAChR.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

Review 5.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

6.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

Review 7.  Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.

Authors:  R Exley; S J Cragg
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

8.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

Review 9.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

Review 10.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.